BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Executive Summary

• BriaCell’s subsidiary, BriaPro Therapeutics, has entered a research collaboration with AI‑driven drug discovery firm Receptor.AI to design isoform‑selective anti‑cancer kinase inhibitors.
• The partnership expands BriaCell’s pipeline beyond cell‑based immunotherapy into small‑molecule discovery, aiming to accelerate development of precision oncology therapeutics.
• Both companies will combine Receptor.AI’s AI platform with BriaPro’s proprietary technology for target assessment, hit identification, and lead optimization across multiple cancer indications.

Key Details

• Collaboration Scope: Integration of Receptor.AI’s multi‑platform AI drug discovery ecosystem (small molecules, peptides, induced‑proximity) with BriaPro’s small‑molecule pipeline to design selective kinase inhibitors.
• Objective: Achieve isoform‑level selectivity for kinases, addressing a major optimization challenge in oncology and enhancing immune‑mediated tumor targeting.
• Roles: Receptor.AI will conduct AI‑driven target assessment, hit identification, and lead optimization; BriaPro will provide proprietary technology and biological expertise.
• Strategic Significance: Marks BriaCell’s first formal expansion into small‑molecule discovery, complementing its existing cell‑based immunotherapy programs.
• Quotes:
• “This partnership marks an important step in BriaCell’s strategic expansion beyond cell‑based immunotherapy into small‑molecule discovery…” – Dr. William V. Williams, President & CEO, BriaCell/BriaPro.
• “Kinase selectivity… remains one of the hardest optimization problems in oncology… This collaboration is about bringing disciplined, AI‑first molecular design and rigorous ADMET constraints to BriaCell’s oncology programs.” – Dr. Alan Nafiev, CEO & Founder, Receptor.AI.

Notable Quotes

• Dr. William V. Williams: “This partnership marks an important step in BriaCell’s strategic expansion beyond cell‑based immunotherapy into small‑molecule discovery, reinforcing its mission to deliver differentiated and complementary approaches to cancer treatment.”
• Dr. Alan Nafiev: “Kinase selectivity, down to the isoform level, remains one of the hardest optimization problems in oncology… This collaboration is about bringing disciplined, AI‑first molecular design and rigorous ADMET constraints to BriaCell’s oncology programs, enhancing precision and translational confidence from the earliest stages of discovery.”